Donal N. Gorman
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Leveraging generative AI to transform statistical analysis plan authoring in clinical trials.
Journal: Clinical trials (London, England)
Published: March 04, 2026
Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.
Journal: Diabetes, obesity & metabolism
Published: December 22, 2024
Practical Aspects of Using Large Language Models to Screen Abstracts for Cardiovascular Drug Development: Cross-Sectional Study.
Journal: JMIR medical informatics
Published: July 09, 2024
Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.
Journal: Journal of clinical pharmacology
Published: August 01, 2023
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Journal: JAMA network open
Published: May 22, 2023
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Journal: Diabetes, obesity & metabolism
Published: February 23, 2023
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
Journal: Diabetes, obesity & metabolism
Published: September 12, 2022
Feasibility study of computational occupational dosimetry: evaluating a proof-of-concept in an endovascular and interventional cardiology setting.
Journal: Journal of radiological protection : official journal of the Society for Radiological Protection
Published: May 17, 2022
A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
Journal: Pharmacology research & perspectives
Published: January 12, 2021
PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis.
Journal: Kidney international reports
Published: December 18, 2020
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Journal: Journal of Parkinson's disease
Published: February 03, 2020
Last Updated: 09/26/2026